HCM Gets NMPA Approval for ELUNATE Combo Therapy, 63% Reduced Disease Progression Risk, 22.2 Months Median PFS in FRUSICA-2 Trial
HUTCHMED (China) Limited American Depositary Shares · Now $11.40
-2.7% in 3d after detection
Post-detection moves
1h
—
1d
-0.4%
3d
-2.7%
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS